Anna L. Lazzell

2.3k total citations · 1 hit paper
26 papers, 1.9k citations indexed

About

Anna L. Lazzell is a scholar working on Epidemiology, Infectious Diseases and Molecular Biology. According to data from OpenAlex, Anna L. Lazzell has authored 26 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Epidemiology, 21 papers in Infectious Diseases and 6 papers in Molecular Biology. Recurrent topics in Anna L. Lazzell's work include Antifungal resistance and susceptibility (21 papers), Fungal Infections and Studies (20 papers) and Probiotics and Fermented Foods (6 papers). Anna L. Lazzell is often cited by papers focused on Antifungal resistance and susceptibility (21 papers), Fungal Infections and Studies (20 papers) and Probiotics and Fermented Foods (6 papers). Anna L. Lazzell collaborates with scholars based in United States, Spain and United Kingdom. Anna L. Lazzell's co-authors include José L. López-Ribot, Carlos Monteagudo, Stephen P. Saville, Christopher G. Pierce, David Kadosh, Mohua Banerjee, Patricia L. Carlisle, Ashok K. Chaturvedi, Joel B. Baseman and Derek P. Thomas and has published in prestigious journals such as Proceedings of the National Academy of Sciences, PLoS ONE and Journal of Clinical Microbiology.

In The Last Decade

Anna L. Lazzell

26 papers receiving 1.9k citations

Hit Papers

EngineeredControl of Cell... 2003 2026 2010 2018 2003 100 200 300 400 500

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna L. Lazzell United States 19 1.5k 1.1k 652 306 215 26 1.9k
Paula Sundstrom United States 28 2.1k 1.5× 1.4k 1.3× 1.1k 1.7× 401 1.3× 200 0.9× 39 2.8k
Marianne Kretschmar Germany 18 1.1k 0.8× 878 0.8× 454 0.7× 269 0.9× 85 0.4× 29 1.6k
Norma V. Solis United States 32 2.1k 1.4× 1.4k 1.3× 945 1.4× 284 0.9× 204 0.9× 75 2.8k
Glen E. Palmer United States 21 1.1k 0.7× 776 0.7× 380 0.6× 128 0.4× 264 1.2× 50 1.5k
Matthew B. Lohse United States 18 1.0k 0.7× 603 0.6× 742 1.1× 265 0.9× 121 0.6× 30 1.6k
Iuliana V. Ene United States 19 1.3k 0.9× 856 0.8× 716 1.1× 271 0.9× 86 0.4× 28 1.8k
Chantal Fradin France 22 1.2k 0.8× 835 0.8× 629 1.0× 218 0.7× 84 0.4× 45 1.8k
Klaus Schröppel Germany 29 1.9k 1.3× 1.4k 1.3× 1.3k 2.0× 273 0.9× 151 0.7× 53 3.0k
Lucía Monteoliva Spain 24 722 0.5× 497 0.5× 856 1.3× 226 0.7× 119 0.6× 49 1.5k
Mette D. Jacobsen United Kingdom 19 1.3k 0.9× 909 0.9× 457 0.7× 241 0.8× 82 0.4× 26 1.6k

Countries citing papers authored by Anna L. Lazzell

Since Specialization
Citations

This map shows the geographic impact of Anna L. Lazzell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna L. Lazzell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna L. Lazzell more than expected).

Fields of papers citing papers by Anna L. Lazzell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna L. Lazzell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna L. Lazzell. The network helps show where Anna L. Lazzell may publish in the future.

Co-authorship network of co-authors of Anna L. Lazzell

This figure shows the co-authorship network connecting the top 25 collaborators of Anna L. Lazzell. A scholar is included among the top collaborators of Anna L. Lazzell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna L. Lazzell. Anna L. Lazzell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Romo, Jesús A., Christopher G. Pierce, Ashok K. Chaturvedi, et al.. (2017). Development of Anti-Virulence Approaches for Candidiasis via a Novel Series of Small-Molecule Inhibitors of Candida albicans Filamentation. mBio. 8(6). 89 indexed citations
2.
Cleary, Ian A., Anna L. Lazzell, Carlos Monteagudo, et al.. (2016). Examination of the pathogenic potential ofC. albicansfilamentous cells in an animal model of haematogenously disseminated candidiasis. FEMS Yeast Research. 16(2). fow011–fow011. 18 indexed citations
3.
Pierce, Christopher G., Ashok K. Chaturvedi, Anna L. Lazzell, et al.. (2015). A novel small molecule inhibitor of Candida albicans biofilm formation, filamentation and virulence with low potential for the development of resistance. npj Biofilms and Microbiomes. 1(1). 98 indexed citations
4.
Cleary, Ian A., Anna L. Lazzell, Carlos Monteagudo, Derek P. Thomas, & Stephen P. Saville. (2012). BRG1 and NRG1 form a novel feedback circuit regulating Candida albicans hypha formation and virulence. Molecular Microbiology. 85(3). 557–573. 65 indexed citations
5.
Martins, Margarida Isabel Barros Coelho, Anna L. Lazzell, José L. López-Ribot, Mariana Henriques, & Rosário Oliveira. (2011). Effect of exogenous administration of Candida albicans autoregulatory alcohols in a murine model of hematogenously disseminated candidiasis. Journal of Basic Microbiology. 52(4). 487–491. 15 indexed citations
6.
Chaturvedi, Ashok K., Anna L. Lazzell, Stephen P. Saville, et al.. (2011). Validation of the Tetracycline Regulatable Gene Expression System for the Study of the Pathogenesis of Infectious Disease. PLoS ONE. 6(5). e20449–e20449. 5 indexed citations
7.
Cleary, Ian A., Craig Murdoch, Martin H. Thornhill, et al.. (2010). Pseudohyphal Regulation by the Transcription Factor Rfg1p in Candida albicans. Eukaryotic Cell. 9(9). 1363–1373. 23 indexed citations
8.
Lazzell, Anna L., Atul Chaturvedi, Christopher G. Pierce, et al.. (2009). Treatment and prevention of Candida albicans biofilms with caspofungin in a novel central venous catheter murine model of candidiasis. Journal of Antimicrobial Chemotherapy. 64(3). 567–570. 85 indexed citations
9.
Saville, Stephen P., Anna L. Lazzell, Ashok K. Chaturvedi, Carlos Monteagudo, & José L. López-Ribot. (2009). Efficacy of a Genetically EngineeredCandida albicans tet-NRG1Strain as an Experimental Live Attenuated Vaccine against Hematogenously Disseminated Candidiasis. Clinical and Vaccine Immunology. 16(3). 430–432. 40 indexed citations
10.
Banerjee, Mohua, Anna L. Lazzell, Patricia L. Carlisle, et al.. (2008). UME6, a Novel Filament-specific Regulator ofCandida albicansHyphal Extension and Virulence. Molecular Biology of the Cell. 19(4). 1354–1365. 211 indexed citations
11.
Banerjee, Asok, Heather Jensen‐Smith, Anna L. Lazzell, et al.. (2008). Localization of βv tubulin in the cochlea and cultured cells with a novel monoclonal antibody. Cell Motility and the Cytoskeleton. 65(6). 505–514. 8 indexed citations
12.
Carlisle, Patricia L., Mohua Banerjee, Anna L. Lazzell, et al.. (2008). Expression levels of a filament-specific transcriptional regulator are sufficient to determine Candida albicans morphology and virulence. Proceedings of the National Academy of Sciences. 106(2). 599–604. 183 indexed citations
13.
Lee, Samuel A., Sarah E. Hardison, Stella M. Bernardo, et al.. (2008). Candida albicans VPS4 is Required for Secretion of Aspartyl Proteases and In Vivo Virulence. Mycopathologia. 167(2). 55–63. 25 indexed citations
14.
Saville, Stephen P., Anna L. Lazzell, Ashok K. Chaturvedi, Carlos Monteagudo, & José L. López-Ribot. (2007). Use of a Genetically Engineered Strain To Evaluate the Pathogenic Potential of Yeast Cell and Filamentous Forms duringCandida albicansSystemic Infection in Immunodeficient Mice. Infection and Immunity. 76(1). 97–102. 35 indexed citations
15.
Thomas, Derek P., A Viudes, Carlos Monteagudo, et al.. (2006). A proteomic‐based approach for the identification of Candida albicans protein components present in a subunit vaccine that protects against disseminated candidiasis. PROTEOMICS. 6(22). 6033–6041. 34 indexed citations
16.
Viudes, A, Anna L. Lazzell, Sofía Perea, et al.. (2004). The C-terminal antibody binding domain ofCandida albicansmp58 represents a protective epitope during candidiasis. FEMS Microbiology Letters. 232(2). 133–138. 25 indexed citations
17.
Monteagudo, Carlos, A Viudes, Anna L. Lazzell, Juan‐Pablo Martínez, & José L. López-Ribot. (2004). Tissue invasiveness and non-acidic pH in human candidiasis correlate with “in vivo” expression by Candida albicans of the carbohydrate epitope recognised by new monoclonal antibody 1H4. Journal of Clinical Pathology. 57(6). 598–603. 7 indexed citations
18.
Saville, Stephen P., Anna L. Lazzell, Carlos Monteagudo, & José L. López-Ribot. (2003). EngineeredControl of Cell Morphology In Vivo Reveals Distinct Roles for Yeast andFilamentous Forms of Candida albicans duringInfection. Eukaryotic Cell. 2(5). 1053–1060. 519 indexed citations breakdown →
19.
ROSE, D. L., et al.. (1995). Mycoplasma pneumoniae and Mycoplasma genitalium mixture in synovial fluid isolate. Journal of Clinical Microbiology. 33(7). 1851–1855. 2 indexed citations
20.
Morrison-Plummer, J, Anna L. Lazzell, & Joel B. Baseman. (1987). Shared epitopes between Mycoplasma pneumoniae major adhesin protein P1 and a 140-kilodalton protein of Mycoplasma genitalium. Infection and Immunity. 55(1). 49–56. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026